Idarucizumab for Dabigatran Reversal | NEJM
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study | SpringerLink
Design of the Reversal Effects of Idarucizumab on Active Dabigatran... | Download Scientific Diagram
Clinical Evidence | Praxbind® (idarucizumab)
Praxbind Full Prescribing Information, Dosage & Side Effects | MIMS Thailand
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis - MPR
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French phar
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Idarucizumab for Dabigatran Reversal – The Bottom Line
Idarucizumab | Circulation
Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant - Labiotech.eu
PDF) Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Clinical Evidence | Praxbind® (idarucizumab)
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination - Stephan Glund, Guanfa Gan, Viktoria Moschetti, Paul Reilly, Markus Honickel, Oliver Grottke, Joanne Van Ryn,
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects - ScienceDirect
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND® (idarucizumab) injection, for intravenous useInitial U.S. Approval: 2015
Clinical Effectiveness of Idarucizumab in Dabigatran Reversal | Wang | Journal of Cardiology and Therapy
Idarucizumab: Plenty of optimism, not enough science - First10EM
Idarucizumab (PRAXBIND) | STROKE MANUAL
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study - Research and Practice in Thrombosis and Haemostasis
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols - ScienceDirect
Idarucizumab for Reversal of Dabigatran – Core EM
Idarucizumab, the Sequel – Emergency Medicine Literature of Note
